Pancreatic Cancer Research

ResearcherMasaryk UniversityActive in the last 2 years

Michal Eid

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4433-5326; OpenAlex author ID A5081216218. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 12

  1. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  2. Ex-Vivo 3D Cellular Models of Pancreatic Ductal Adenocarcinoma: From Embryonic Development to Precision Oncology. Co-author DOI 10.1097/mpa.0000000000002393↗
  3. Artificial intelligence in pancreatic cancer histopathology and diagnostics - implications for clinical decisions and biomarker discovery? First author DOI 10.1186/s13008-025-00158-w↗
  4. Integrated clinical-bio logical infrastructure for precision oncology in pancreatic adenocarcinoma - experience with REDCap implementation in an academic setti… Last author DOI 10.48095/ccko2025464↗
  5. Minimal invasive surgery of pancreatic cancer at the Department of Surgery of Masaryk university hospital Brno, Czech Republic. Co-author DOI 10.33699/pis.2024.103.4.122-131↗
  6. Gut microbio-me and pancreatic cancer. Co-author DOI 10.48095/ccko202420↗
  7. The role of neoadjuvant treatment in localized pancreatic cancer. First author DOI 10.48095/ccrvch2024429↗
  8. Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration. Co-author DOI 10.3390/biomedicines10102480↗
  9. Current trends in the diagnosis of pancreatic cancer. First author DOI 10.36290/vnl.2022.076↗
  10. The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. Co-author DOI 10.3390/biomedicines9101468↗
  11. Is autoimmune pancreatitis a risk factor for pancreatic adenocarcinoma? Co-author DOI 10.36290/vnl.2021.011↗
  12. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. Co-author DOI 10.4149/neo_2020_200408n372↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jan Hlavsa · 5 shared papers, 2021–2025 · strength 1.02
  2. Petr Moravčík · 4 shared papers, 2024–2025 · strength 0.90
  3. Vladimír Procházka · 4 shared papers, 2024–2025 · strength 0.90
  4. Radim Němeček · 3 shared papers, 2022–2026 · strength 0.85
  5. Petr Vaňhara · 3 shared papers, 2025 · strength 0.72
  6. Zdeněk Kala · 4 shared papers, 2021–2025 · strength 0.70
  7. Lumír Kunovský · 4 shared papers, 2021–2022 · strength 0.56
  8. Petra Weselá · 2 shared papers, 2025 · strength 0.51
  9. Ivana Aćimović · 2 shared papers, 2025 · strength 0.45
  10. Arnošt Martínek · 2 shared papers, 2021–2024 · strength 0.40
  11. Petr Dítě DrSc · 2 shared papers, 2021–2024 · strength 0.40
  12. Jan Trna · 2 shared papers, 2021–2022 · strength 0.27
  13. Ondřej Slabý · 2 shared papers, 2021 · strength 0.25
  14. Jiřı́ Mayer · 2 shared papers, 2021 · strength 0.25
  15. Annalisa Comandatore · 1 shared paper, 2026 · strength 0.24
  16. Ingrid Garajová · 1 shared paper, 2026 · strength 0.24
  17. Luca Morelli · 1 shared paper, 2026 · strength 0.24
  18. Geert Kazemier M · 1 shared paper, 2026 · strength 0.24
  19. Carsten Palnæs Hansen · 1 shared paper, 2026 · strength 0.24
  20. Elisa Giovannetti · 1 shared paper, 2026 · strength 0.24
  21. Inna Markovna Chen · 1 shared paper, 2026 · strength 0.24
  22. Ján Trnka · 1 shared paper, 2025 · strength 0.22
  23. Stanislava Martínková · 1 shared paper, 2025 · strength 0.22
  24. Petr Vaněk · 1 shared paper, 2022 · strength 0.19
  25. Miroslav Vrzal · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.